Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-centre cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry

被引：0
|
作者：
Li, Angelo [1 ]
Musters, Annelie H. [1 ]
Hyseni, Arienna [1 ]
Gerbens, Louise A. A. [1 ,2 ]
Spuls, Phyllis, I [1 ,2 ]
机构：
[1] Univ Amsterdam, Amsterdam UMC, Dept Dermatol, Amsterdam, Netherlands
[2] Univ Amsterdam, Amsterdam Publ Hlth Infect & Immun, Amsterdam UMC, Amsterdam, Netherlands
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷 / 06期
关键词：
PLACEBO;
D O I：
10.1093/bjd/ljae289
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
This study investigated the incidence and progression of (hyper)eosinophilia in patients with atopic dermatitis (AD) treated with dupilumab, using data from the TREAT NL registry cohort. In total, 38.5% of patients had (hyper)eosinophilia at baseline and/or during dupilumab treatment. (Hyper)eosinophilia was present at baseline in 43 (55.8%) patients and developed in 34 (44.2%) patients during treatment. Eosinophilia was transient, peaking at 6 months and normalizing by 18-24 months. One patient discontinued dupilumab due to persistent hypereosinophilia, but generally, eosinophilia did not affect treatment outcomes. In conclusion, dupilumab is found viable for patients with AD regardless of baseline eosinophilia, with temporary increases in eosinophil counts that are often not clinically significant.
引用
收藏
页码：1012 / 1013
页数：2
相关论文
共 10 条
  • [1] Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry
    Bosma, Angela L.
    de Wijs, Linde E. M.
    Hof, Michel H.
    van Nieuwenhuizen, Beau R.
    Gerbens, Louise A. A.
    Middelkamp-Hup, Maritza A.
    Hijnen, DirkJan
    Spuls, Phyllis, I
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) : 1375 - 1384
  • [2] TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema
    Bosma, A. L.
    Spuls, P. I.
    Garcia-Doval, I.
    Naldi, L.
    Prieto-Merino, D.
    Tesch, F.
    Apfelbacher, C. J.
    Arents, B. W. M.
    Barbarot, S.
    Baselga, E.
    Deleuran, M.
    Eichenfield, L. F.
    Gerbens, L. A. A.
    Irvine, A. D.
    Manca, A.
    Mendes-Bastos, P.
    Middelkamp-Hup, M. A.
    Roberts, A.
    Seneschal, J.
    Svensson, A.
    Thyssen, J. P.
    Torres, T.
    Vermeulen, F. M.
    Vestergaard, C.
    von Kobyletzki, L. B.
    Wall, D.
    Weidinger, S.
    Schmitt, J.
    Flohr, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (06) : 1423 - 1429
  • [3] Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry
    Musters, A. H.
    van Lookeren, F. L.
    van der Gang, L. F.
    Middelkamp-Hup, M. A.
    Bosma, A. L.
    Jessurun, N. T.
    Lapeere, H.
    Nguyen, A. L.
    Ouwerkerk, W.
    de Schepper, S.
    Gerbens, L. A. A.
    Spuls, P. I.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (03) : 530 - 542
  • [4] Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study
    Uchida, H.
    Kamata, M.
    Mizukawa, I.
    Watanabe, A.
    Agematsu, A.
    Nagata, M.
    Fukaya, S.
    Hayashi, K.
    Fukuyasu, A.
    Tanaka, T.
    Ishikawa, T.
    Ohnishi, T.
    Tada, Y.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (05) : 1083 - 1085
  • [5] Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study
    Napolitano, Maddalena
    Fabbrocini, Gabriella
    Patruno, Cataldo
    JOURNAL OF DERMATOLOGY, 2023, 50 (07) : 880 - 887
  • [6] Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry
    Ariens, Lieneke F. M.
    van der Schaft, Jorien
    Bakker, Daphne S.
    Balak, Deepak
    Romeijn, Margreet L. E.
    Kouwenhoven, Tessa
    Kamsteeg, Marijke
    Giovannone, Barbara
    Drylewicz, Julia
    van Amerongen, Cynthia Catalina Aurora
    Delemarre, Evelien M.
    Knol, Edward F.
    van Wijk, Femke
    Nierkens, Stefan
    Thijs, Judith L.
    Schuttelaar, Marie L. A.
    de Bruin-Weller, Marjolein S.
    ALLERGY, 2020, 75 (01) : 116 - 126
  • [7] Switching from baricitinib to dupilumab as an advanced-line treatment in pediatric patients with atopic dermatitis: a retrospective cohort study
    Ollech, Ayelet
    Cohen-Barak, Eran
    Horev, Amir
    Bar-Ilan, Efrat
    Greenberger, Shoshana
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, 63 (07) : e130 - e132
  • [8] The efficacy and safety of dupilumab for the treatment of atopic dermatitis among Chinese patients in clinical practice: A single-center retrospective study
    Li, Ying
    Lu, Jiajing
    Chen, Rongfen
    Wang, Yu
    Ding, Yangfeng
    Xu, Shuang
    Zou, Ying
    Yi, Xuemei
    Shi, Yuling
    DERMATOLOGIC THERAPY, 2022, 35 (05)
  • [9] Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis 1-Year Results From the RELIEVE-AD Study
    Strober, Bruce
    Mallya, Usha G.
    Yang, Min
    Ganguli, Sohini
    Gadkari, Abhijit
    Wang, Jessie
    Sierka, Debra
    Delevry, Dimittri
    Kimball, Alexa B.
    JAMA DERMATOLOGY, 2022, 158 (02) : 142 - 150
  • [10] Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort study
    Kridin, Khalaf
    Schonmann, Yochai
    Solomon, Arie
    Onn, Erez
    Bitan, Dana Tzur
    Weinstein, Orly
    Cohen, Arnon D.
    IMMUNOLOGIC RESEARCH, 2022, 70 (01) : 106 - 113
1